Arbutus Biopharma Corporation (NASDAQ:ABUS) has earned a consensus recommendation of “Buy” from the eight analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $14.75.

A number of analysts have weighed in on ABUS shares. Leerink Swann reaffirmed a “market perform” rating and issued a $5.00 price target (up previously from $4.00) on shares of Arbutus Biopharma in a research report on Tuesday, November 7th. ValuEngine raised Arbutus Biopharma from a “sell” rating to a “hold” rating in a research report on Thursday, September 21st. Chardan Capital reaffirmed a “buy” rating on shares of Arbutus Biopharma in a research report on Monday, August 7th. Wedbush reaffirmed an “outperform” rating and issued a $9.00 price target on shares of Arbutus Biopharma in a research report on Wednesday, September 20th. Finally, Zacks Investment Research raised Arbutus Biopharma from a “sell” rating to a “hold” rating in a research report on Tuesday, November 7th.

Shares of Arbutus Biopharma (NASDAQ:ABUS) traded down $0.10 during trading hours on Friday, hitting $5.55. The company’s stock had a trading volume of 193,691 shares, compared to its average volume of 233,422. Arbutus Biopharma has a 12 month low of $2.35 and a 12 month high of $8.25. The company has a quick ratio of 11.03, a current ratio of 11.03 and a debt-to-equity ratio of 0.08.

In other Arbutus Biopharma news, insider Michael J. Sofia sold 10,000 shares of the business’s stock in a transaction dated Tuesday, October 3rd. The stock was sold at an average price of $8.00, for a total value of $80,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 10.00% of the stock is owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Arbutus Biopharma by 2.7% in the 2nd quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock valued at $279,000 after purchasing an additional 2,035 shares during the period. Bank of Montreal Can lifted its stake in shares of Arbutus Biopharma by 1.9% in the 2nd quarter. Bank of Montreal Can now owns 874,254 shares of the biopharmaceutical company’s stock valued at $3,147,000 after purchasing an additional 16,535 shares during the period. OxFORD Asset Management LLP lifted its stake in shares of Arbutus Biopharma by 89.9% in the 2nd quarter. OxFORD Asset Management LLP now owns 83,310 shares of the biopharmaceutical company’s stock valued at $300,000 after purchasing an additional 39,436 shares during the period. RTW Investments LP increased its position in shares of Arbutus Biopharma by 1.1% in the 3rd quarter. RTW Investments LP now owns 5,266,280 shares of the biopharmaceutical company’s stock valued at $32,651,000 after buying an additional 56,457 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Arbutus Biopharma by 785.1% during the 1st quarter. Renaissance Technologies LLC now owns 124,573 shares of the biopharmaceutical company’s stock worth $405,000 after purchasing an additional 110,499 shares in the last quarter. Institutional investors own 60.00% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Arbutus Biopharma Corporation (ABUS) Receives Consensus Recommendation of “Buy” from Analysts” was posted by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/12/01/arbutus-biopharma-corporation-abus-receives-consensus-recommendation-of-buy-from-analysts.html.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.